Analyst Ratings For Avacta Group Plc (LON:AVCT)
Today, FinnCap reiterated its Corporate rating on Avacta Group Plc (LON:AVCT) with a price target of GBX 200.
There are 1 buy rating on the stock.
The current consensus rating on Avacta Group Plc (LON:AVCT) is Buy (Score: 3.00) with a consensus target price of GBX 200 per share, a potential .
Some recent analyst ratings include
- 2/24/2017-FinnCap Reiterated Rating of Corporate.
- 8/1/2016-Numis Securities Ltd Reiterated Rating of Buy.
About Avacta Group Plc (LON:AVCT)
Avacta Group plc is a biotechnology company. Avacta’s focus is on its proprietary Affimer technology which is an engineered alternative to antibodies that has application in Life Sciences for diagnostics, therapeutics and general research and development. Affimer technology has been designed to address performance limitations of antibodies. Affimer technology is based on a small protein that can be generated to bind with specificity and affinity to a range of targets to enable diagnostics, research assays and therapeutics. Avacta has a pre-clinical therapeutic development programme with an in-house focus on immuno-oncology and bleeding disorders as well as partnered development programmes. Avacta is commercialising non-therapeutic Affimer reagents through licensing to developers of life sciences research tools and diagnostics.
Recent Trading Activity for Avacta Group Plc (LON:AVCT)
Shares of Avacta Group Plc closed the previous trading session at 66.75 down -0.75 -1.11% with 0 shares trading hands.
